ASRV presents a classic deep-value paradox: it is significantly undervalued relative to its Graham Number ($7.43) and Intrinsic Value ($10.03), trading at a low P/B of 0.54. However, the Piotroski F-Score of 3/9 indicates weak fundamental health, suggesting deteriorating operational efficiency or financial stability. While earnings growth is explosive at 74.8% YoY, the low ROE (4.95%) and bearish technical trend (10/100) offset the valuation appeal. The stock is a high-risk value play where the margin of safety is countered by poor health metrics.